RecruitingPhase 2NCT04770207
Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
Intra-tumor Injection of Drug-eluting Microspheres Loading With Chemodrug Plus Checkpoint Inhibitors and/or IL2 for Treatment of Advanced Solid Tumors
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Enrollment
100 participants
Start Date
Nov 1, 2020
Study Type
INTERVENTIONAL
Conditions
Summary
To study the safety and clinical effect of injection of drug-eluting microspheres with multiple chemodrug and/or protein drugs into advanced solid tumors.
Eligibility
Min Age: 18 YearsMax Age: 99 Years
Inclusion Criteria3
- Solid advanced malignant tumors
- Age between18 and 99 years
- Life expectancy is greater than three months
Exclusion Criteria4
- Benign tumor
- Life expectancy is less than three months
- Serious medical comorbidity
- Others
Interventions
DRUGInjection of drug-eluting microspheres with multiple drugs into solid tumors
Under the guidance of CT, puncture fine needle was used to inject drug-eluting microspheres loading with multiple drugs into the tumor
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04770207
Related Trials
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT0624477126 locations
64Cu-GRIP B in Patients With Advanced Malignancies
NCT058885321 location
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NCT0621891418 locations
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT0662577531 locations
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
NCT0605169512 locations